Press Releases

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Paris, October 1st, 2020 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully […]
Read more

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

UN PROGRAMME NATIONAL POUR PROMOUVOIR ET ACCOMPAGNER LES FUTURS LEADERS TECHNOLOGIQUES DANS LEUR DEVELOPPEMENT INTERNATIONAL Paris, le 21 janvier 2020 – ACTICOR Biotech, société de biotechnologie en phase clinique impliquée dans la phase aiguë des maladies thrombotiques, y compris les accidents vasculaires cérébraux ischémiques aigus, annonce aujourd’hui avoir intégré la première promotion du French Tech […]
Read more

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Paris, November 5th 2019 – Acticor Biotech, a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations. Led by Professor Mikael Mazighi from Paris University, who is neurologist at Lariboisière Hospital […]
Read more

Acticor Biotech raises €15.3M in a Series B financing

Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first […]
Read more

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Paris, July 31, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an Asset Transfer and Licensing agreement covering a development and commercialisation collaboration agreement with CMS Medical Limited as well as an investment agreement with CMS Medical […]
Read more
Page 1 of 41234